Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Garnick

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Cancer Treatment Reports|September 1, 1979
Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and adriamycinM B Garnick, G P Canellos, J P Richie, et al.
Human Pathology|October 1, 1988
Silicone lymphadenopathy in a long distance runner: complication of a silastic prosthesisL A Rogers, J A Longtine, M B Garnick, et al.
The New England Journal of Medicine|April 19, 1990
Biology and management of bladder cancerD Raghavan, W U Shipley, M B Garnick, et al.
The Journal of Urology|December 1, 1988
Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal diseaseM A Socinski, M B Garnick, P C Stomper, et al.
The Journal of Urology|September 1, 1987
Cavitary lung nodules associated with combination chemotherapy containing bleomycinJ A Talcott, M B Garnick, P C Stomper, et al.
Annals of Internal Medicine|January 1, 1989
Nodular pneumonitis after cancer chemotherapyJ A Talcott, M B Garnick, P C Stomper, et al.
Urology|October 1, 1996
Leydig cell hyperplasia mimicking testicular neoplasmA F Olumi, M B Garnick, A A Renshaw, et al.
Urology|November 17, 2001
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerD McLeod, N Zinner, K Tomera, et al.
Radiology|September 1, 1991
CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?P C Stomper, L A Kalish, M B Garnick, et al.
Blood|February 15, 1990
In vivo hematologic effects of recombinant human macrophage colony-stimulating factorT R Ulich, J del Castillo, L R Watson, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Cancer Treatment Reports|September 1, 1979
Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and adriamycinM B Garnick, G P Canellos, J P Richie, et al.
Human Pathology|October 1, 1988
Silicone lymphadenopathy in a long distance runner: complication of a silastic prosthesisL A Rogers, J A Longtine, M B Garnick, et al.
The New England Journal of Medicine|April 19, 1990
Biology and management of bladder cancerD Raghavan, W U Shipley, M B Garnick, et al.
The Journal of Urology|December 1, 1988
Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal diseaseM A Socinski, M B Garnick, P C Stomper, et al.
The Journal of Urology|September 1, 1987
Cavitary lung nodules associated with combination chemotherapy containing bleomycinJ A Talcott, M B Garnick, P C Stomper, et al.
Annals of Internal Medicine|January 1, 1989
Nodular pneumonitis after cancer chemotherapyJ A Talcott, M B Garnick, P C Stomper, et al.
Urology|October 1, 1996
Leydig cell hyperplasia mimicking testicular neoplasmA F Olumi, M B Garnick, A A Renshaw, et al.
Urology|November 17, 2001
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerD McLeod, N Zinner, K Tomera, et al.
Radiology|September 1, 1991
CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?P C Stomper, L A Kalish, M B Garnick, et al.
Blood|February 15, 1990
In vivo hematologic effects of recombinant human macrophage colony-stimulating factorT R Ulich, J del Castillo, L R Watson, et al.
Pageof 13